Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SASCIA: Sacituzumab Govitecan in High Relapse Risk HER2-negative Breast Cancer
NCT04595565Phase 3Active, not recruiting
- Sponsor
- GBG Forschungs
- Start
- Oct 2020
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of sacituzumab govitecan in breast cancer, triple-negative breast cancer (TNBC), sponsored by GBG Forschungs. Started Oct 2020; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04595565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595565.